Philippines vs Tajikistan: Average cost of drugs for extensively drug-resistant tuberculosis
Philippines
282 constant 2022 US$
in 2024
Tajikistan
257 constant 2022 US$
in 2024
Philippines rank
52nd
Tajikistan rank
53rd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Philippines
- Tajikistan
How they compare
Philippines currently reports 282 constant 2022 US$ against 257 constant 2022 US$ in Tajikistan, a difference of 25 constant 2022 US$.
That makes Philippines's figure about 1.1 times Tajikistan's.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Philippines ahead.
Philippines ranks 52nd and Tajikistan ranks 53rd of 56 countries.
Philippines has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Philippines | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 8,943 constant 2022 US$ | 4,438 constant 2022 US$ | 4,506 constant 2022 US$ | Philippines |
| 2020s | 3,710 constant 2022 US$ | 1,849 constant 2022 US$ | 1,861 constant 2022 US$ | Philippines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Philippines or Tajikistan?
- Philippines, at 282 constant 2022 US$ against 257 constant 2022 US$ in Tajikistan as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Philippines and Tajikistan?
- 25 constant 2022 US$, with Philippines ahead.
- How many years of comparable data are there for Philippines and Tajikistan?
- 7 years are reported by both, from 2017 to 2024.
- How do Philippines and Tajikistan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Philippines ranks 52nd and Tajikistan ranks 53rd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.